Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Summary

This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy

Timeline

Start

2021-10-30

Primary completion

2023-09-30

Completion

2024-12-01

Publications

• Zhang Y, Zou Q, Zhao B, Su N, Li Z, Wang X, Liu P, Tian X, Fang X, Cai J, Li L, Liu Y, Xia Y, Cai Q. Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL). Cell Rep Med. 2024 Dec 17;5(12):101833. doi: 10.1016/j.xcrm.2024.101833. Epub 2024 Nov 29.

Drugs

Indications